16366
64 / Wednesday, April 4, 2007 / Notices
jlentini on PROD1PC65 with NOTICES
VerDate Aug<31>2005
Federal Register / Vol. 72, No.
Trans No.
20070928 .........................
20070932 .........................
20070940 .........................
20070944 .........................
20070949 .........................
20070950 .........................
20070951 .........................
20070952 .........................
20070953 .........................
20070954 .........................
20070968 .........................
20070970 .........................
20070971 .........................
20070974 .........................
20070975 .........................
20070977 .........................
20070982 .........................
20070984 .........................
20070986 .........................
20070991 .........................
20070995 .........................
For Further Information Contact:
Sandra M. Peay, Contact Representative
or Renee Hallman, Contact
Representative. Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room H–
303, Washington, DC 20580, (202) 326–
3100.
By Direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 07–1646 Filed 4–3–07; 8:45 am]
BILLING CODE 6750–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the National Coordinator for
Health Information Technology;
American Health Information
Community Population Health and
Clinical Care Connections Workgroup
Meeting
ACTION: Meeting cancellation.
SUMMARY: This notice announces the
cancellation of the 15th meeting of the
American Health Information
Community Population Health and
Clinical Care Connections Workgroup
[formerly Biosurvellance Workgroup] in
accordance with the Federal Advisory
Committee Act (Pub. L. 92–463, 5
U.S.C., App.)
17:57 Apr 03, 2007
Acquiring Acquired Entities
Aktiegolaget Volvo ............................. Ingersoll-Rand Company Limited ...... Blaw-Knox Construction Equipment
Corporation.
Beacon Roofing Supply, Inc .............. North Coast Commercial Roofing North Coast Commercial Roofing
Systems, Inc. Systems, Inc.
OCM Principal Opportunities Fund EXCO Resources, Inc ....................... EXCO Resources, Inc.
IV, lL.P.
OCM Opportunities Fund VII, L.P ..... EXCO Resources, Inc ....................... EXCO Resources, Inc.
Ambassadors international, Inc ......... Carnival Corporation ......................... Windstar Sail Cruises Limited.
AP Berry Holdings, LLC .................... Berry Plastics Group, Inc .................. Berry Plastics Group, Inc.
Vestar Capital Partners V, L.P .......... Paul Danton (Dan) Huish .................. Huish Detergents, Inc.
Graham Partners II, L.P .................... Berry Plastics Group, Inc .................. Berry Plastics Group, Inc.
Apollo Investment Fund VI, L.P ........ Berry Plastics Group, Inc .................. Berry Plastics Group, Inc.
Apollo Investment Fund V, L.P ......... Apollo Investment Fund VI, L.P ........ Berry Plastics Group, Inc.
Iconix Brand Group, Inc .................... ROCSAN Holdings, LLC ................... ROCAWEAR LICENSING, LLC.
John D. Baker II ................................ Holdco ............................................... Holdco.
Monomoy Capital Partners, L.P ........ Global Home Products LLP, Chapter Anchor Hocking CG Operating Com-
11 debtor in possession. pany, LLC; Anchor Hocking Oper-
ating Company, LLC, Anchor
Hocking Operating Company LLC.
Zurich Financial Services .................. Bristol West Holdings, Inc ................. Bristol West Holdings, Inc.
IDB Holding Corporation Ltd ............. Susan W. Shoval ............................... Guard Financial Group, Inc.
LPL Investment Holdings, Inc ........... Pacific Mutual Holding Company ...... Pacific Select Group LLC.
Spire Capital Partners II, L.P ............ Professional Bull Riders, Inc ............. Professional Bull Riders, Inc.
Marathon Special Opportunity Master SPX Corporation ............................... General Signal UK Ltd.
Fund, Ltd.
CRFRC–D Holdings, Inc ................... DEG Acquisitions, LLC ...................... DEG Acquisitions, LLC.
Ares Corporate Opportunities Fund, EXCO Resources, Inc ....................... EXCO Resources, Inc.
L.P.
JLL Partners Fund, V, L.P ................ Patheon Inc ....................................... Patheon Inc.
CANCELED DATE/TIME: April 20, 2007, in science findings of the U.S. Public
from 10 a.m., to 3:30 p.m. Eastern Health Service (PHS) in the following
Daylight Time. case:
ADDRESSES: Hubert H. Humphrey Rebecca Uzelmeier (formerly known
Building (200 Independence Avenue, as Rebecca Marcus), Michigan State
SW., Washington, DC 20201), Room University: Based on the report of an
505A. Please bring photo ID for entry to investigation by Michigan State
a Federal building). University (MSU) and additional
information obtained by the Office of
FOR FURTHER INFORMATION CONTACT:
Research Integrity (ORI) during its
http://www.hhs.gov/healthit/ahic/ oversight review, ORI found that
population/. Rebecca Uzelmeier, former doctoral
Dated: March 27, 2007. student, Department of Pharmacology
Judith Sparrow, and Toxicology, MSU, committed
Director, American Health Information misconduct in science by intentionally
Community, Office of Programs and and knowingly fabricating and falsifying
Coordination, Office of the National data in research supported by National
Coordinator for Health Information Institute of Environmental Health
Technology. Sciences (NIEHS), National Institutes of
[FR Doc. 07–1645 Filed 4–3–07; 8:45 am] Health (NIH), granted R01 ES02520.
BILLING CODE 4150–24–M ORI issued a charge letter
enumerating the above findings of
misconduct in science. However, on
DEPARTMENT OF HEALTH AND October 12, 2006, Ms. Uzelmeier filed a
HUMAN SERVICES request for a hearing under 42 CFR part
93 to dispute these findings before the
Office of the Secretary U.S. Department of Health and Human
Services (HHS) Departmental Appeals
Findings of Misconduct in Science
Board (DAB). On October 19, 2006, ORI
AGENCY: Office of the Secretary, HHS. moved to dismiss Ms. Uzelmeier’s
ACTION: Notice. hearing request because it failed to
create a genuine dispute of either
SUMMARY: Notice is hereby given that on material fact or law, as required under
March 12, 2007 the Department of 42 CFR 93.504. On March 5, 2007, the
Health and Human Services (HHS) Administrative Law Judge (ALJ) with
Debarring Official, on behalf of the the DAB ruled in ORI’s favor and
Secretary of HHS, issued a final notice dismissed Ms. Uzelmeier’s hearing
of debarment based on the misconduct request pursuant to 42 CFR 93.504(a)(2).
Jkt 211001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\04APN1.SGM 04APN1
 Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices
The ALJ found that Ms. Uzelmeier’s
hearing request raised defenses that
either were immaterial to the charges of
misconduct in science or that the ALJ
had no authority to grant Ms.
Uzelmeier’s request for relief under Part
93.
Specifically, Ms. Uzelmeier
knowingly and intentionally;
• Fabricated and falsified data in her
research notebook primarily by multiple
instances of using data/results generated
from one experiment to represent data/
results purportedly obtained from one
or more entirely different experiments;
and
• Fabricated and falsified data in her
thesis entitled ‘‘Characterization of the
Molecular Mechanism(s) Underlying the
Interaction(s) between 2,3,7,8-
tetrachlorodibenzo-p-Dioxin Mediated
and Interferon Gamma Mediated Signal
Transduction,’’ including falsifying and
fabricating autoradiographic films,
computer image files scanned from
those films, numerical data reduced
from those computer files,
documentation of those results in her
black three-ring binder, and data in
associated multiple figures and
projection slides.
Ms. Uzlmeier’s research concerned
the interaction between the
environmental toxin, dioxin, and a
cytokine, interferon, on cellular
signaling in the immune system. The
approach was to exploit dioxin, or
‘‘TCDD’’ (2,3,7,8-tetrachlorodibenzo-p-
dioxin), as a probe that suppresses the
immune system to delineate a role for
the aryl hydrocarbon receptor protein
(AhR), which is a cytosolic receptor that
can be transported to the nucleus to also
act as a nuclear transcription factor. The
specific aim was to determine whether
the mechanism of action of a naturally
occurring regulatory factor, interferon-g
(IFN-g), to antagonize the
immunosuppressive actions of dioxin,
was through reduced AhR signaling.
Ms. Uzelmeier’s actions caused the
withdrawal of a manuscript that had
been submitted for publication, the
withdrawal of her mentor’s PHS grant
application, and her dismissal from
graduate school.
The following administrative actions
have been implemented for a period of
five (5) years, beginning on March 12,
2007:
(1) Ms. Uzelmeier has been debarred
from any contracting or subcontracting
with any agency of the United States
jlentini on PROD1PC65 with NOTICES
Government and from eligibility or
involvement in nonprocurement
programs of the United States
Government referred to as ‘‘covered
transactions’’ as defined in the
VerDate Aug<31>2005 17:57 Apr 03, 2007 Jkt 211001
debarment regulations at 2 CFR 180 and
376; and
(2) Ms. Uzelmeier is prohibited from
serving in any advisory capacity to PHS
including but not limited to service on
any PHS advisory committee, board,
and/or peer review committee, or as
consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. 07–1616 Filed 4–3–07; 8:45 am]
BILLING CODE 4160–17–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Solicitation for Nominations for
Members of the U.S. Preventive
Services Task Force
AGENCY: Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Solicits nominations for new
members.
SUMMARY: The Agency for Healthcare
Research and Quality (AHRQ) invites
nominations of individuals qualified to
serve as members of the U.S. Preventive
Services Task Force (the Task Force).
The Task Force, a standing,
independent panel of private-sector
experts in prevention and primary care,
is composed of members appointed to
serve for four-year terms with an option
for reappointment. New members are
selected each year to replace
(approximately) one fourth of the Task
Force members, i.e., those who are
completing their appointments.
Individuals nominated but not
appointed in previous years, as well as
those newly nominated, are considered
in the annual selection process.
Task Force members meet three times
a year for two days in the Washington,
DC area. Member duties include
reviewing and preparing comments (off
site) on systematic evidence reviews
prior to discussing and making
recommendations on preventive
services, drafting final recommendation
documents, and participating in
workgroups on specific topics or
methods. AHRQ particularly encourages
nominations of women, members of
minority populations, and persons with
disabilities. Interested individuals can
self nominate. Organizations and
individuals may nominate one or more
PO 00000 Frm 00043 Fmt 4703 Sfmt 4703
16367
persons qualified for membership on the
Task Force.
Qualification Requirements: The
mission of the Task Force is to produce
evidence-based recommendations on
the appropriate screening, counseling,
and provision of preventive medication
for asymptomatic patients seen in the
primary care setting. Therefore, in order
to qualify for the Task Force, an
applicant or nominee MUST
demonstrate the following:
1. Knowledge and experience in the
critical evaluation of research published
in peer reviewed literature and in the
methods of evidence review;
2. Understanding and experience in
the application of synthesized evidence
to clinical decision-making and/or
policy;
3. Expertise in disease prevention and
health promotion;
4. Ability to work collaboratively with
peers; and,
5. Clinical expertise in the primary
health care of children and/or adults,
and/or expertise in counseling and
behavioral interventions for primary
care patients. Some Task Force members
without primary health care clinical
experience may be selected based on
their expertise in methodological issues
such as medical decision making,
clinical epidemiology, behavioral
medicine, and health economics.
Strongest consideration will be given
to individuals who are recognized
nationally or intentionally for scientific
leadership within their field of
expertise. Applicants must have no
substantial conflicts of interest that
would impair the scientific integrity of
the work of the Task Force including
financial, intellectual, or other conflicts.
DATES: All nominations submitted in
writing or electronically, and received
by Thursday, May 31, 2007, will be
considered for appointment to the Task
Force.
Nominated individuals will be
selected for the Task Force on the basis
of their qualifications (in particular,
those that address the required
qualifications, outlined above) and the
current expertise needs of the Task
Force. It is anticipated that 4
individuals will be invited to serve on
the Task Force beginning in January,
2008. AHRQ will retain and consider for
future vacancies the nominations of
those not selected during this cycle.
ADDRESSES: Submit your responses
either in writing or electronically to:
Gloria Washington, ATTN: USPSTF
Nominations, Center for Primary Care,
Prevention, and Clinical Partnerships,
Agency for Healthcare Research and
Quality, 540 Gaither Road, Rockville,
E:\FR\FM\04APN1.SGM 04APN1